RU2272627C1 - Preparation for treatment and prophylaxis of mastitis in cows at onset of lactation period and in dry cows - Google Patents

Abstract

FIELD: veterinary science.

SUBSTANCE: invention proposes a preparation for treatment and prophylaxis of mastitis in cows at onset of the lactation period and in dry cows that comprises the following components, wt.-%: furacrylin, 0.4-0.6; dioxydin, 0.8-1.2; bee wax, 4-6, and sunflower oil, the balance. The preparation is heated to 38-40°C and administrated in cow mammary gland being in damaged and healthy lobules of udder through a nipple duct by using a syringe in the dose 5 ml. Using the preparation provides enhancing therapeutic and prophylactic effectiveness, decreasing labor intensity in treatment and prophylaxis of mastitis in cows at the lactation period and in dry cows.

EFFECT: enhanced and valuable properties of preparation.

3 tbl, 3 ex

Description

The invention relates to the field of veterinary medicine, can be used for the treatment and prevention of mastitis in cows in the dry period and during start-up.

Mastitis is an inflammation of the mammary gland that occurs in various physiological periods in cows.

Mastitis in cows is widespread at the end of lactation, during start-up and in the dry period, as well as after childbirth.

A number of analogues are known to be used to treat mastitis in cows. For example, Masticide / 1 /, Mastisan A / 2 /, Mastisan B / 3 /, Mastisan E / 4 /, Mastisan / 5 /, Furakhin / 6 /, Masta - 30/7 /.

However, these preparations contain antibiotics and sulfanilamines, the use of which currently has a number of negative aspects (the rapid development of resistant strains of microorganisms, inhibition of the protective mechanisms of microorganisms and the appearance of mastitis of mycotic etiology, the occurrence of allergies and anaphylaxis in animals and humans).

The prototype of the invention is the drug Difumast / 8 /.

The composition of the drug Difumast is as follows:

Dioxidine 2%;

Furacilin 0.04%;

Beeswax 5%;

Vaseline oil - the rest.

The drug is a homogeneous oily yellow liquid. Dioxidin in combination with furatsilinom gives a good effect in relation to gram-positive and gram-negative microorganisms, anaerobes, protozoa.

The main disadvantage of the prototype is low therapeutic efficacy due to the fact that the microflora isolated from the mammary gland of cows is weakly sensitive or insensitive to active components (dioxidine, furacryline).

Another drawback is the need for multiple introductions of the udder into the tank (4 or more times), which increases the labor costs of veterinarians, negatively affects the condition of the mucous membrane of the nipple canal and the mammary gland tank.

The technical result of the invention is an increase in therapeutic and prophylactic effectiveness, a decrease in the complexity of the treatment and prevention of mastitis in cows during the start-up period and dead wood.

In addition, as a result, the quality of milk improves, milk production increases, the number of rejected animals decreases and the cost of treating sick animals is reduced, cows are cured in the last decade of lactation and only healthy cows are launched so that the processes of mammary gland involution proceed normally.

The goal is achieved by using a composite preparation consisting of the following components, wt.%:

Furacryline - 0.4-0.6;

Dioxidine - 0.8-1.2;

Beeswax - 4-6;

Sunflower oil - the rest.

In this case, the optimal ratio of components is the following (wt.%):

Furacryline - 0.5;

Dioxidine - 1;

Beeswax - 5;

Sunflower oil - the rest.

Dioksidin-1,4-di-N-oxide 2,3 bio (oxymethyl) quinoxaline is a chemotherapeutic drug characterized by activity in infections caused by gram-positive and gram-negative bacteria 191.

Furacrilin-1-5-nitrofuryl acrylidene-amino-1,3,4-triazole / 10 /.

Furacryline is a derivative of 5-nitrofuryl acrolein. It has a pronounced antimicrobial effect against staphylococci, streptococci, Escherichia coli and hay bacillus, various types of salmonella, a vulgar protein, Shigella microorganisms at a concentration of 0.2-13.0 μg / ml. The mechanism of antimicrobial action of furacrilin is explained by a violation of DNA synthesis in the microbial cell. Furacrilin belongs to the class of low toxic substances of the sixth row. To it, unlike antibiotics, the resistance of microorganisms slowly develops. It does not inhibit the natural protective mechanisms of the animal’s body, it stimulates the phagocytic activity of leukocytes, the secretion of the udder, and blood.

The composition of the claimed drug also includes beeswax, which contributes to the slow absorption of the drug, thereby increasing the duration of the drug, which is an important point in prevention and therapy during the start-up and dead season. Sunflower oil plays the role of a filler.

The drug is used as follows. When heated to 38-40 ° C, the form is injected into the mammary gland of cows, both in the affected and in mastite-free lobes, through the nipple canal in a dose of 5 ml once with a syringe. Thus, the use of the drug reduces the complexity. The prototype (Difumast) is introduced repeatedly into the udder tank (4 or more times), which increases the labor costs of veterinarians and, in addition, negatively affects the condition of the mucous membrane of the nipple canal and the mammary gland tank.

The drug is made as follows (in parentheses - an indication in wt.% The number of components). Sunflower oil (the rest) and beeswax (5%) are melted at a temperature of 60 ° C, then the active substances - Furakrilin (0.5%) and Dioxidine (1%) are added.

The tests to verify the effectiveness of the drug were carried out at the experimental station of VGAU, GPOKH VNIISS of the Ramonsky district of the Voronezh region, FGU 11113 "Kirovsky" of the Novousmansky district of the Voronezh region, GSH "Petrovsky" Dobrinsky district of the Lipetsk region.

The essence of the proposed technical solution is illustrated by examples.

Example 1. Irritating effect on the mammary gland of cows.

3 clinically healthy lactating cows were selected. The drug in the optimal ratio of components (Furakrilin - 0.5; Dioxidin - 1; beeswax - 5; sunflower oil - the rest), heated to a temperature of 38 ° C in an amount of 5 ml was injected intracisternally into the left front part of the udder after preliminary secretion and processing nipple 70 ° ethanol. The drug was not injected into the right anterior lobe; it served as a control. Before the introduction of the drug and after 3, 6, 12, 24, 48, 72, and 96 hours, a general clinical examination of the animals, mammary gland, and reaction with a 2% mastidine solution was performed. The number of somatic cells was counted in the laboratory and the assay sample was taken into account. The results of the experiment are presented in table 1.

Table 1
The change in the content of somatic cells in the secret of the udder of healthy cows after intracisternal administration of the claimed drug. Udder shares Study Dates before introduction 3 hours 6 o'clock 12 hours 24 hours 48 hours 72 hours amount C K thousand / ml Left front (experience) 376.6 ± 12.1 425.8 ± 13.6 710.3 ± 13.2 1234.3 ± 42.1 1473.3 ± 15.6 734.6 ± 18.5 398.6 ± 10.9 Right front (control) 377.2 ± 11.2 477.0 ± 12.3 579.3 ± 20.7 639.3 ± 14.3 676.0 ± 14.9 568.6 ± 12.1 382.0 ± 11.2

In the study of secretion with a 2% mastidine solution, a dubious reaction and an increase in somatic cells were observed in all animals 3 hours after the administration of the drug. By 24 hours after administration of the drug, a maximum increase in somatic cells to 1473.3 thousand / ml is observed, and by 72 hours the number of somatic cells is below 500 thousand / ml.

Example 2. The effectiveness of the claimed drug for the treatment of subclinical mastitis in cows in the dry period.

Four groups of cows of the Holstein-Friesian breed of the second and fourth lactation were selected. The diagnosis was made according to a study with a 2% mastidine solution.

To the cows of the experimental groups, the claimed preparation was administered intracesternally once at a dose of 5 ml in a form heated to 38 ° C in various ratios of active components, wt.%:

Recipe 1.

Furacryline - 0.5;

Dioxidine - 1;

Wax - 5;

Sunflower oil - the rest.

Recipe 2.

Furacryline - 0.4;

Dioxidine - 0.8;

Wax - 4;

Sunflower oil - the rest.

Recipe 3.

Furacryline - 0.6;

Dioxidine - 1.2;

Wax - 6;

Sunflower oil - the rest.

The animals of the control group were injected with Difumast intracisternally at a dose of 5 ml in a form warmed up to 38 ° C in accordance with the instructions for the drug / 9 /.

The animals were monitored, the therapeutic effectiveness of the drug was determined by the incidence of cows after calving with subclinical mastitis. The results of the experiment are presented in table 2.

table 2
Therapeutic efficacy of the claimed drug in subclinical mastitis in cows A drug amount Recovered Left sick Cows share cows % share % cows % share % atrophy % The inventive, rec. 1. 90 130 86 95.8 119 91.5 four 4.2 eleven 8.5 - - Difumast 99 216 76 76.8 161 74.5 23 23,2 51 23.6 four 1.9 The inventive, rec.2. 82 124 73 89.0 105 84.6 9 11.0 19 15.4 - - The inventive, rec. 3. 85 162 81 95.3 148 91.4 four 4.7 fourteen 8.6 - -

From table 2 it follows that the best therapeutic effect is achieved when using the composition of dioxidine, furacryline and beeswax in a ratio of 1.0: 0.5: 5.0.

Example 3. The effectiveness of the claimed drug for the prevention of subclinical mastitis in cows in the dry period.

Five groups of 2-4 lactation Holstein-Friesian cows were selected. The diagnosis was made according to a study with a 2% mastidine solution.

The animals of the first group were administered the claimed drug according to the recipe 1:

Furacryline - 0.5;

Dioxidine - 1;

Wax - 5;

Sunflower oil - the rest.

The drug was administered intracisternally once at a dose of 5 ml in the form heated to 38 ° C.

The animals of the third group were injected with the inventive formulation 2:

Furacryline - 0.4;

Dioxidine - 0.8;

Wax - 4;

Sunflower oil - the rest.

The drug was administered intracisternally once at a dose of 5 ml in the form heated to 38 ° C.

Animals of the fourth group were injected with the claimed drug according to the recipe 3:

Furacryline - 0.6;

Dioxidine - 1.2;

Wax - 6;

Sunflower oil - the rest.

The drug was administered intracisternally once at a dose of 5 ml in the form heated to 38 ° C.

A fifth group of animals served as a negative control. The animals were monitored, the preventive effectiveness of the drug was determined by the incidence of cows, after calving, subclinical mastitis.

Table 3
The effectiveness of the proposed drug and prototype for the prevention of subclinical mastitis in cows in the dry period A drug amount Do not get mastitis Mastitis cows share cows % share % cows % share % atrophy % The inventive, rec. 1. 40 157 39 97.5 152 96.8 one 2,5 5 3.2 - - Difumast thirty 118 26 86.7 95 80.5 four 13.3 23 19.5 - - The inventive, rec.2. 38 152 34 89.5 135 88.8 four 10.5 17 11.2 - - The inventive, rec. 3. 40 149 39 97.5 143 96.0 one 2,5 6 4.0 - - The control 48 189 33 68.7 126 66.6 fifteen 31.3 57 30,2 6 3.2

Thus, the studies showed high therapeutic and prophylactic efficacy of the claimed drug. Using the proposed technical solution can significantly reduce the labor costs of veterinary specialists.

Information sources

1. Masticide. Instruction for use. Approved by the General Directorate of Veterinary of the Ministry of Agriculture of the USSR 08/17/1977

2. Mastisan A. Instruction for use. Approved by the Main Veterinary Administration of the Ministry of Agriculture of the USSR on October 25, 1982

3. Mastisan B. Instruction for use. Approved by the Main Veterinary Administration of the Ministry of Agriculture of the USSR on 10/22/1982

4. Mastisan E. Instruction for use. Approved by the Main Veterinary Administration of the Ministry of Agriculture of the USSR on 10/22/1982

5. Balkova I.I. The effectiveness of the fight against mastitis in cows // Questions of veterinary pharmacy and pharmacotherapy: Abstracts. doc. All scientific and practical. conf. - Riga, 1982. - S.73-75.

6. Savostin A. N. The use of furachin for the treatment and prevention of subclinical mastitis in cows in the dry period: Abstract. dis .. cand. vet. Sciences / A.N. Savostin. - Voronezh, 1988 - 24 p.

7. Polyantsev N.I. Treatment of subclinical mastitis / Polyantsev N.I. // Veterinary medicine - 1997. No. 12. - p. 37-39.

8. Difumast is an anti-mastitis drug. Permanent instruction for use. Approved by the Veterinary Department of the Ministry of Agriculture of the Russian Federation on July 29, 02. g.

9. Instructions for the use of dioxidine, Ministry of Health of the USSR. 12/23/1982

10. Morgunov V.I. Pharmaco-toxicological properties of furacrilin. / Abstract of dissertation for the degree of candidate of veterinary sciences. - Voronezh, 1922.

Claims (1)

A drug for the treatment and prevention of mastitis in cows during the start-up period and dead wood, containing bees dioxin and wax, characterized in that it additionally contains furacryline and sunflower oil in the following ratio of components wt.%: Furacryline 0.4-0.6 Dioxidine 0.8-1.2 Beeswax 4-6 Sunflower oil Rest.